Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (481-490 of 595) with videos related to

Pageof 60
Sort By:
Diabetes Care|November 1, 1987
U-100 insulin gives some protection against metabolic deterioration due to CSII interruptionA J Scheen, P Henrivaux, B Jandrain, et al.
Diabete & Metabolisme|January 1, 1988
The intra-nasal administration of insulin induces significant hypoglycaemia and classical counterregulatory hormonal responses in normal manN Paquot, A J Scheen, P Franchimont, et al.
Acta Endocrinologica|November 1, 1987
The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretionM Castillô, A J Scheen, G Paolisso, et al.
Revue Medicale De Liege|May 17, 2002
[Postprandial hyperglycemia. I. Physiopathology, clinical consequences and dietary management]A J Scheen, N Paquot, B Jandrain, et al.
Revue Medicale De Liege|April 7, 2017
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER]A J Scheen, L Piérard, J-M Krzesinski, et al.
Revue Medicale De Liege|March 22, 2019
[Management of hypertriglyceridaemia]A J Scheen, C Wallemacq, J De Flines, et al.
Diabetes & Metabolism|December 19, 2016
Factors associated with reaching or not reaching target HbA<sub>1c</sub> after initiation of basal or premixed insulin in patients with type 2 diabetesA J Scheen, H Schmitt, H H Jiang, et al.
Revue Medicale De Liege|February 11, 2010
[Management of an obese person with metabolic syndrome]M Rorive, J De Flines, N Paquot, et al.
Revue Medicale De Liege|August 1, 2009
[Monoclonal antibodies in diabetes: almost approaching the dream?]J C Philips, B Keymeulen, C Mathieu, et al.
Revue Medicale De Liege|August 6, 2010
[Strategies avoiding inertia and non compliance in clinical trials]B J Jandrain, Ph Ernest, R P Radermecker, et al.
Pageof 60

Showing results (481-490 of 595) with videos related to

Sort By:
Pageof 60
Diabetes Care|November 1, 1987
U-100 insulin gives some protection against metabolic deterioration due to CSII interruptionA J Scheen, P Henrivaux, B Jandrain, et al.
Diabete & Metabolisme|January 1, 1988
The intra-nasal administration of insulin induces significant hypoglycaemia and classical counterregulatory hormonal responses in normal manN Paquot, A J Scheen, P Franchimont, et al.
Acta Endocrinologica|November 1, 1987
The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretionM Castillô, A J Scheen, G Paolisso, et al.
Revue Medicale De Liege|May 17, 2002
[Postprandial hyperglycemia. I. Physiopathology, clinical consequences and dietary management]A J Scheen, N Paquot, B Jandrain, et al.
Revue Medicale De Liege|April 7, 2017
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER]A J Scheen, L Piérard, J-M Krzesinski, et al.
Revue Medicale De Liege|March 22, 2019
[Management of hypertriglyceridaemia]A J Scheen, C Wallemacq, J De Flines, et al.
Diabetes & Metabolism|December 19, 2016
Factors associated with reaching or not reaching target HbA<sub>1c</sub> after initiation of basal or premixed insulin in patients with type 2 diabetesA J Scheen, H Schmitt, H H Jiang, et al.
Revue Medicale De Liege|February 11, 2010
[Management of an obese person with metabolic syndrome]M Rorive, J De Flines, N Paquot, et al.
Revue Medicale De Liege|August 1, 2009
[Monoclonal antibodies in diabetes: almost approaching the dream?]J C Philips, B Keymeulen, C Mathieu, et al.
Revue Medicale De Liege|August 6, 2010
[Strategies avoiding inertia and non compliance in clinical trials]B J Jandrain, Ph Ernest, R P Radermecker, et al.
Pageof 60